SANGAMO THERAPEUTICS INC (SGMO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SGMO • US8006771062

0.3943 USD
-0.01 (-1.43%)
Last: Feb 9, 2026, 09:38 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SGMO. SGMO was compared to 523 industry peers in the Biotechnology industry. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability. SGMO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SGMO has reported negative net income.
  • In the past year SGMO has reported a negative cash flow from operations.
  • In the past 5 years SGMO always reported negative net income.
  • SGMO had negative operating cash flow in 4 of the past 5 years.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • With a Return On Assets value of -122.86%, SGMO is not doing good in the industry: 78.97% of the companies in the same industry are doing better.
  • The Return On Equity of SGMO (-1744.50%) is worse than 80.50% of its industry peers.
Industry RankSector Rank
ROA -122.86%
ROE -1744.5%
ROIC N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • SGMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SGMO has more shares outstanding than it did 1 year ago.
  • SGMO has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • SGMO has an Altman-Z score of -27.90. This is a bad value and indicates that SGMO is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of SGMO (-27.90) is worse than 86.04% of its industry peers.
  • There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.9
ROIC/WACCN/A
WACC12.44%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • SGMO has a Current Ratio of 0.88. This is a bad value and indicates that SGMO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.88, SGMO is doing worse than 86.62% of the companies in the same industry.
  • SGMO has a Quick Ratio of 0.88. This is a bad value and indicates that SGMO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.88, SGMO is doing worse than 86.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • SGMO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.33%, which is quite impressive.
  • The Revenue for SGMO has decreased by -37.70% in the past year. This is quite bad
  • Measured over the past years, SGMO shows a very negative growth in Revenue. The Revenue has been decreasing by -10.81% on average per year.
EPS 1Y (TTM)41.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
Revenue 1Y (TTM)-37.7%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%-98.82%

3.2 Future

  • SGMO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.05% yearly.
  • Based on estimates for the next years, SGMO will show a very strong growth in Revenue. The Revenue will grow by 46.03% on average per year.
EPS Next Y34.48%
EPS Next 2Y20.77%
EPS Next 3Y28.61%
EPS Next 5Y29.05%
Revenue Next Year-1.84%
Revenue Next 2Y-10.68%
Revenue Next 3Y39.81%
Revenue Next 5Y46.03%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • SGMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SGMO's earnings are expected to grow with 28.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.77%
EPS Next 3Y28.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SGMO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (2/9/2026, 9:38:50 AM)

0.3943

-0.01 (-1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners18.72%
Inst Owner Change-6.11%
Ins Owners1.31%
Ins Owner Change-5.81%
Market Cap132.68M
Revenue(TTM)32.88M
Net Income(TTM)-108.91M
Analysts78.33
Price Target3.89 (886.56%)
Short Float %6.34%
Short Ratio3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31749.3%
Min EPS beat(2)-63537.1%
Max EPS beat(2)38.49%
EPS beat(4)1
Avg EPS beat(4)-15880.5%
Min EPS beat(4)-63537.1%
Max EPS beat(4)38.49%
EPS beat(8)2
Avg EPS beat(8)-7919.96%
EPS beat(12)4
Avg EPS beat(12)-5281.72%
EPS beat(16)8
Avg EPS beat(16)-3957.71%
Revenue beat(2)0
Avg Revenue beat(2)-70.85%
Min Revenue beat(2)-98.34%
Max Revenue beat(2)-43.35%
Revenue beat(4)0
Avg Revenue beat(4)-50.56%
Min Revenue beat(4)-98.34%
Max Revenue beat(4)-14.91%
Revenue beat(8)1
Avg Revenue beat(8)-37.03%
Revenue beat(12)2
Avg Revenue beat(12)15.02%
Revenue beat(16)5
Avg Revenue beat(16)12.37%
PT rev (1m)17.31%
PT rev (3m)-7.01%
EPS NQ rev (1m)13.29%
EPS NQ rev (3m)38.27%
EPS NY rev (1m)4.75%
EPS NY rev (3m)-14.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)54.02%
Revenue NY rev (1m)10.68%
Revenue NY rev (3m)-18.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.04
P/FCF N/A
P/OCF N/A
P/B 21.25
P/tB 21.25
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.1
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.86%
ROE -1744.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.66%
Cap/Sales 0.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -27.9
F-Score4
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)104.2%
Cap/Depr(5y)163.67%
Cap/Sales(3y)10.21%
Cap/Sales(5y)12.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
EPS Next Y34.48%
EPS Next 2Y20.77%
EPS Next 3Y28.61%
EPS Next 5Y29.05%
Revenue 1Y (TTM)-37.7%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%-98.82%
Revenue Next Year-1.84%
Revenue Next 2Y-10.68%
Revenue Next 3Y39.81%
Revenue Next 5Y46.03%
EBIT growth 1Y35.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.95%
EBIT Next 3Y-31.75%
EBIT Next 5Y34.36%
FCF growth 1Y70.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.07%
OCF growth 3YN/A
OCF growth 5YN/A

SANGAMO THERAPEUTICS INC / SGMO FAQ

What is the ChartMill fundamental rating of SANGAMO THERAPEUTICS INC (SGMO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SGMO.


What is the valuation status for SGMO stock?

ChartMill assigns a valuation rating of 1 / 10 to SANGAMO THERAPEUTICS INC (SGMO). This can be considered as Overvalued.


Can you provide the profitability details for SANGAMO THERAPEUTICS INC?

SANGAMO THERAPEUTICS INC (SGMO) has a profitability rating of 0 / 10.